Hui Yu

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib

Y. Wang, Tao Jiang, Zhen Qin et al. · Annals of Oncology · 2018 · 217 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer

Ze-Rui Zhao, Chaopin Yang, Si Chen et al. · OncoImmunology · 2021 · 120 citations · Full text

Medicine, Oncology, Pharmacology +17

Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

Mingzhi Zhang, Dan Chen, Xiaorui Fu et al. · Clinical Cancer Research · 2022 · 113 citations · Full text

Life Sciences, Immunology, Oncology +17

CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer

Kenichi Suda, Isao Murakami, Hui Yu et al. · Molecular Cancer Therapeutics · 2018 · 47 citations · Full text

Medicine, Cancer Biology, Oncology +16

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer

Yixin Zhou, Yaqiong Zhang, Guifang Guo et al. · Clinical and Translational Medicine · 2020 · 46 citations · Full text

Medicine, Oncology, Pharmacotherapy +17